(Q35069444)

6 August 2017

1 reference

title

Quality control of biotechnology-derived vaccines: technical and regulatory considerations (English)

1 reference

6 August 2017

0 references

0 references

Florence Fuchs

1

1 reference

6 August 2017

1 November 2002

1 reference

6 August 2017

1 reference

6 August 2017

84

1 reference

6 August 2017

11

1 reference

6 August 2017

1173-1179

1 reference

Gene therapy and viral vaccination: the interface

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Oral immunization with hepatitis B surface antigen expressed in transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Phytosecretion of enteropathogenic Escherichia coli pilin subunit A in transgenic tobacco and its suitability for early life vaccinology

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Oral immunisation of naive and primed animals with transgenic potato tubers expressing LT-B

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Expression of rabies virus glycoprotein from a recombinant vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Characterization of a recombinant fowlpox virus expressing the native hexon of hemorrhagic enteritis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Lentiviral vectors for sustained transgene expression in human bone marrow-derived stromal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children

1 reference

https://api.crossref.org/works/10.1016%2FS0300-9084%2802%2900028-7

7 January 2021

10.1016/S0300-9084(02)00028-7

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12595146